AUTL250117C1500
- 0.00
- 0.000.00%
Autolus Therapeutics Newsroom
Truist Financial Maintains Autolus Therapeutics(AUTL.US) With Buy Rating
Autolus Therapeutics (AUTL) Gets a Buy From Truist Financial
Autolus Therapeutics to Present Key Data on AUCATZYL At 2025 Tandem Meetings, Highlighting Cost Benefits and Clinical Outcomes
Wells Fargo Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $8
Positive Buy Rating for Autolus Therapeutics Driven by Aucatzyl's Promising Launch and Strategic Growth Prospects
Autolus Reports FDA Approval and NCCN Inclusion of AUCATZYL, Sets Milestones for Pipeline Growth
Press Release: Autolus Therapeutics Provides Business Updates and 2025 Overview
Why Autolus Therapeutics (AUTL) Is One of the Best Biotech Penny Stocks to Invest in Now?
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Reported Earlier, Autolus Therapeutics Revealed New Data Supporting Obe-cel's Clinical And Economic Benefits At ASH 2024
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics: Undervalued Potential in ALL Treatment With Obe-cel
Autolus Therapeutics Plc (AUTL): A Bull Case Theory
Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Autolus Therapeutics Announces Publication of Data From the FELIX Study of Obe-cel in R/r Adult B-ALL Patients in The New England Journal of Medicine
Is Autolus Therapeutics (NASDAQ:AUTL) Using Too Much Debt?
European Equities Traded in the US as American Depositary Decline in Tuesday Trading
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings